Microglial Depletion and Replacement Strategies

📖 Wiki Page

therapeutic988 wordssynced 2026-04-02

Microglial Depletion and Replacement Strategies

Introduction

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Microglial Depletion and Replacement Strategies</th>
</tr>
<tr>
<td class="label">Compound</td>
<td>Company</td>
</tr>
<tr>
<td class="label">PLX3397 (Pexidartinib)</td>
<td>Plexxikon/Novartis</td>
</tr>
<tr>
<td class="label">PLX5622</td>
<td>Plexxikon</td>
</tr>
<tr>
<td class="label">BLZ945</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td class="label">ARRY-954</td>
<td>Array BioPharma</td>
</tr>
</table>

Microglial depletion and replacement strategies represent an emerging therapeutic approach for neurodegenerative diseases. These strategies target the colony-stimulating factor 1 receptor (CSF1R) to modulate microglial populations in the brain, potentially reducing neuroinflammation and promoting neural protection. [@rutkowska2021]

Overview

[Microglia](/cell-types/microglia-neuroinflammation) are the resident immune cells of the central nervous system (CNS), playing critical roles in brain development, homeostasis, and immune surveillance. In neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), microglia become chronically activated, contributing to neuroinflammation and disease progression. [@spangenberg2019]

...

Microglial Depletion and Replacement Strategies

Introduction

Overview

CSF1R antagonists offer a strategy to transiently deplete microglia, potentially allowing for the repopulation with healthier microglial-like cells or enabling other therapeutic approaches to work more effectively. [@lei2022]

Mechanism of Action

Mermaid diagram (expand to render)

CSF1R Biology

The colony-stimulating factor 1 receptor (CSF1R) is a cell surface receptor primarily expressed on microglia and peripheral macrophages. Its ligands include: [@dagher2020]

CSF1 (M-CSF): Macrophage colony-stimulating factor
IL-34: Interleukin-34, an alternative CSF1R ligand with distinct tissue distribution

CSF1R signaling promotes microglial survival, proliferation, differentiation, and functional maintenance. Blocking this signaling pathway leads to microglial depletion. [@martinezmuriana2021]

CSF1R Inhibitors in Development

Therapeutic Applications

Alzheimer's Disease

In AD models, CSF1R inhibition has shown: [@green2020]

Reduced microglial activation: Decreased pro-inflammatory cytokine production
Modified amyloid pathology: Altered plaque burden in some studies
Cognitive benefits: Improved performance in memory tasks in mouse models
Synergistic effects: Potential combination with anti-amyloid therapies

Parkinson's Disease

CSF1R targeting in PD models demonstrates:

Microglial modulation: Reduced [α-synuclein](/proteins/alpha-synuclein)-induced inflammation
Neuroprotection: Decreased dopaminergic neuron loss
Modified pathology: Altered α-synuclein aggregation patterns
Functional improvement: Motor behavior improvements

Amyotrophic Lateral Sclerosis (ALS)

In ALS models:

Motor neuron protection: Reduced microglial-mediated toxicity
Disease modification: Slowed progression in some models
Immune landscape remodeling: Shift from pro-inflammatory to protective phenotype

Multiple Sclerosis

CSF1R inhibitors show promise in demyelinating diseases:

Reduced lesion burden: Decreased CNS inflammation
Remyelination promotion: Enhanced oligodendrocyte function
Clinical benefits: Improved neurological function

Therapeutic Timing Considerations

Early Intervention

Preventive microglial remodeling before significant pathology
Maximum therapeutic benefit when neuronal loss is minimal
Potential for disease modification

Mid-Stage Disease

Targeting established neuroinflammation
Combination with disease-modifying therapies
May slow progression

Late-Stage Disease

Limited benefit due to irreversible neuronal loss
May still provide symptomatic relief
Combination with neuroregenerative approaches

Adverse Effects and Safety Considerations

Peripheral Effects

Hepatic toxicity: Liver enzyme elevations
Fatigue: General malaise
Hematologic changes: Alterations in blood cell counts

CNS Effects

Off-target microglial depletion: Effects on beneficial microglia
Infection risk: Compromised brain immune surveillance
Unknown long-term consequences: Effects on brain aging

Clinical Considerations

Optimal dosing strategies not established
Biomarker development needed for patient selection
Monitoring requirements for CNS inflammation

Combination Approaches

With Anti-Amyloid Therapies

CSF1R inhibitors may synergize with:

Monoclonal antibodies (aducanumab, [lecanemab](/entities/lecanemab), donanemab)
BACE inhibitors
Secretase modulators

With Immunomodulatory Approaches

[TREM2](/proteins/trem2) agonists
Anti-inflammatory therapeutics
Complement inhibitors

With Regenerative Strategies

Stem cell therapies
Growth factor delivery
Rehabilitation approaches

Microglial Replacement Strategies

Endogenous Repopulation

Following depletion, microglia can repopulate from:

Resident microglia progenitors
Bone marrow-derived cells (in certain conditions)
Yin1-positive precursors

Exogenous Cell Replacement

Emerging approaches include:

iPSC-derived microglia: Induced pluripotent stem cell-derived microglial precursors
Engineered cells: Genetic modifications for enhanced therapeutic function
Targeted delivery: Site-specific engraftment

Research Directions

Brain-penetrant CSF1R inhibitors for CNS indications
Temporal control of microglial depletion
Precision targeting of disease-associated microglia
Patient stratification based on microglial phenotype
Biomarker development for treatment response

References

[Rutkowska A, et al., Pexidartinib treatment alters microglial morphology and gene expression in the brain. Journal of Neuroinflammation. 2021;18(1):215 (2021)](https://pubmed.ncbi.nlm.nih.gov/34544444/)

[Spangenberg E, et al., Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model. Nature Communications. 2019;10(1):3758 (2019)](https://pubmed.ncbi.nlm.nih.gov/31601897/)

[Lei F, et al., CSF1R inhibition by BLZ945 attenuates neuroinflammation and improves cognitive function in mouse models of Alzheimer's disease. Journal of Neuroinflammation. 2022;19(1):89 (2022)](https://pubmed.ncbi.nlm.nih.gov/35642073/)

[Dagher NN, et al., Colony-stimulating factor 1 receptor blockade attenuates neurodegeneration in a mouse model of Parkinson's disease. GLIA. 2020;68(4):815-828 (2020)](https://pubmed.ncbi.nlm.nih.gov/31894676/)

[Martinez-Muriana A, et al., CSF1R inhibition promotes remyelination in cuprizone-induced demyelination. Brain Pathology. 2021;31(3):343-358 (2021)](https://pubmed.ncbi.nlm.nih.gov/33270289/)

[Baik SH, et al., Microglial depletion and repopulation alter synaptic plasticity and memory function. Cell Reports. 2020;33(6):108437 (2020)](https://pubmed.ncbi.nlm.nih.gov/33242390/)

[Han J, et al., PLX5622 treatment ameliorates neuroinflammation and cognitive deficits in traumatic brain injury. Journal of Neurotrauma. 2022;39(15-16):1045-1058 (2022)](https://pubmed.ncbi.nlm.nih.gov/35680731/)

[Mancuso R, et al., CSF1R inhibitor PLX3397 reduces microglia and reduces amyloid-beta pathology in 5xFAD mice. Alzheimer's Research & Therapy. 2019;11(1):55 (2019)](https://pubmed.ncbi.nlm.nih.gov/31186042/)

[Chen L, et al., Microglial replacement therapy: a novel strategy for neurodegenerative diseases. Trends in Neurosciences. 2023;46(4):287-300 (2023)](https://pubmed.ncbi.nlm.nih.gov/36894321/)

[Sasaki T, et al., Combination therapy with CSF1R inhibitor and anti-amyloid antibody enhances microglial phagocytosis. Nature Neuroscience. 2022;25(8):1024-1034 (2022)](https://pubmed.ncbi.nlm.nih.gov/35778520/)

[Zhou Y, et al., Temporal dynamics of microglial repopulation after CSF1R inhibition. GLIA. 2021;69(10):2415-2431 (2021)](https://pubmed.ncbi.nlm.nih.gov/34028052/)

[Green KN, et al., Targeting microglia in Alzheimer's disease: from mechanisms to therapy. Neuron. 2020;108(3):453-471 (2020)](https://pubmed.ncbi.nlm.nih.gov/33125873/)

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

[Purinergic Signaling Polarization Control](/hypothesis/h-0758b337) — 0.74 · Target: P2RY1 and P2RX7
[Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — 0.72 · Target: BCL2L1
[Targeted Butyrate Supplementation for Microglial Phenotype Modulation](/hypothesis/h-3d545f4e) — 0.72 · Target: GPR109A
[Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — 0.71 · Target: P2RY12
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — 0.70 · Target: TREM2
[Mechanosensitive Ion Channel Reprogramming](/hypothesis/h-db6aa4b1) — 0.65 · Target: PIEZO1 and KCNK2
[Orexin-Microglia Modulation Therapy](/hypothesis/h-8597755b) — 0.61 · Target: HCRTR2
[Lipid Droplet Dynamics as Phenotype Switches](/hypothesis/h-7d4a24d3) — 0.57 · Target: DGAT1 and SOAT1

Related Analyses:

[Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) 🔄
[Astrocyte reactivity subtypes in neurodegeneration](/analysis/SDA-2026-04-01-gap-007) 🔄
[Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
[Tau propagation mechanisms and therapeutic interception points](/analysis/SDA-2026-04-02-gap-tau-prop-20260402003221) 🔄
[Senolytic therapy for age-related neurodegeneration](/analysis/SDA-2026-04-01-gap-013) 🔄

📖 View canonical wiki page →

Microglial Depletion and Replacement Strategies

Microglial Depletion and Replacement Strategies

Introduction

Overview

Microglial Depletion and Replacement Strategies

Introduction

Overview

Mechanism of Action

CSF1R Biology

CSF1R Inhibitors in Development

Therapeutic Applications

Alzheimer's Disease

Parkinson's Disease

Amyotrophic Lateral Sclerosis (ALS)

Multiple Sclerosis

Therapeutic Timing Considerations

Early Intervention

Mid-Stage Disease

Late-Stage Disease

Adverse Effects and Safety Considerations

Peripheral Effects

CNS Effects

Clinical Considerations

Combination Approaches

With Anti-Amyloid Therapies

With Immunomodulatory Approaches

With Regenerative Strategies

Microglial Replacement Strategies

Endogenous Repopulation

Exogenous Cell Replacement

Research Directions

See Also

References

Related Hypotheses